Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Lupin receives approval for Bepotastine Tablets – a new second generation Antihistamine

Mumbai, May 22, 2017: Pharma Major Lupin Limited (Lupin) announced today that it has received approval for Bepotastine Tablets from the Central Drugs Standard Control Organisation (CDSCO). Lupin shall commence promoting the product in India shortly.

Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit millions of patients suffering from allergic symptoms. It is a rapid acting antihistamine that effectively controls day time and night time triggers of allergic symptoms. Bepotastine is approved by PMDA Japan and is actively marketed in Japan and other South East Asian countries.

The current market for plain antihistamines is estimated to be around INR 860 crores growing at 14%. (IMS MAT Mar 2017).

Mr. Naresh Gupta, President, Lupin Limited said "We have a rich legacy of addressing medical needs in the country and introducing treatments to combat them. I am sure that the approval of Bepotastine would go a long way in addressing a common medical need for a safe and effective drug for the management of allergic symptoms."

About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 5th and the 6th largest generics pharmaceutical company by market capitalization (December 31st, 2016, Bloomberg) and sales globally (September 30th, 2016, Bloomberg). The Company is the 5th largest pharmaceutical player in the US by prescriptions (4.3% market share – IMS MAT December 2016); the 2nd largest Indian pharmaceutical company by revenues; the 6th largest generic pharmaceutical player in Japan and the 4th largest generic pharmaceutical company in South Africa (IMS Health, March 2016).

For the financial year ended 31st March, 2016, Lupin's Consolidated sales and Net profit stood at Rs. 136,539 million (USD 2.09 billion) and Rs. 22,607 million (USD 345 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Arvind Bothra
Head – Investor Relations and M&A

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Ph: +91-22-66402137
Email: arvindbothra@lupin.com